Human Longevity launched a new company focused on longevity foundation models (HLFM) and partnered with Insilico Medicine to build AI-powered platforms intended to decode aging mechanisms and enable predictive healthcare. Human Longevity said HLFM will use Human Longevity’s clinical datasets, while Insilico brings drug discovery and computational model experience. The companies described the collaboration as multi-year and multi-million-dollar, without disclosing specific figures for this specific arrangement. The effort is positioned around foundation-model approaches to identify interventions that could shift medicine toward prevention and earlier targeting. The move reflects continued appetite for data-heavy longevity and AI discovery infrastructure as biopharma seeks longer-horizon, mechanism-led programs.